Skip to content

Current ratio at other companies

Amgen logo
AmgenAMGN
1.3×+0.1×
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
3.6×-1.4×
Aclaris Therapeutics logo
Aclaris TherapeuticsACRS
-1.0×
Shattuck Labs, Inc. logo
Shattuck Labs, Inc.STTK
22.1×+13.0×
Savara logo
SavaraSVRA
13.5×-1.4×
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
7.6×-0.7×

Other financials

Income statement

See full
Revenue$1.0M+82.7%
Operating income-$43.6M-36.2%
Net income-$40.6M-48.8%
EPS (diluted)-$0.75-47.1%

Balance sheet

See full
Cash & equivalents$96.7M+35.6%
Total debt$1.1M-34.5%
Total equity$304.0M-31.8%
Total assets$318.1M-30.3%

Cash flow

See full
Operating cash flow-$47.9M-16.2%
CapEx$54.0K-70.8%
Free cash flow-$30.7M-55.0%

Valuation

See full
Market cap$346.11M-40.9%
Enterprise value$250.5M-51.4%
P/S104.2×-151×

Profitability

See full
Operating margin-5,176.5%+1,764pp
Net margin-4,719%+2,752pp

Returns & leverage

See full
Return on equity-41.8%
Debt / equity0.0×

Where this comes from

Calculated from Upstream Bio, Inc.’s reported figures.

Based on the most recent quarter.

The official record: Upstream Bio, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Upstream Bio, Inc.'s current ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Upstream Bio, Inc.'s current ratio?
Upstream Bio, Inc. (UPB) reported current ratio of 23.1× in Q1 2026.
How has Upstream Bio, Inc.'s current ratio changed year-over-year?
Upstream Bio, Inc.'s current ratio decreased by 51.2% year-over-year, from 47.4× to 23.1×.
What is the long-term trend for Upstream Bio, Inc.'s current ratio?
Over 2 years (2023 to 2025), Upstream Bio, Inc.'s current ratio has grown at a 20.7% compound annual growth rate (CAGR), from 18× to 26.2×.
What does current ratio mean?
Current assets divided by current liabilities at the quarter end. Measures the company's ability to cover near-term obligations with near-term assets.